BioLine Rx Ltd (BLRX)

1.16
0.06 5.50
NASDAQ : Health Care
Prev Close 1.10
Open 1.10
Day Low/High 1.10 / 1.18
52 Wk Low/High 0.71 / 2.25
Volume 266.29K
Avg Volume 394.10K
Exchange NASDAQ
Shares Outstanding 56.42M
Market Cap 65.45M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY

BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY

- Presentation includes details of 2017 operating plan and five-year Company vision -

BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference

BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference

Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C

BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications

BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications

Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML

BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China

BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China

JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations -

BioLineRx To Report Second Quarter Results On August 11, 2016

BioLineRx To Report Second Quarter Results On August 11, 2016

Management to hold conference call at 10:00 a.m. EDT

BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration

BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration

Novel drug candidate modulates immune system to reduce liver fibrosis in non-alcoholic steatohepatitis

BioLineRx To Report First Quarter 2016 Results On May 17, 2016

BioLineRx To Report First Quarter 2016 Results On May 17, 2016

Management to hold a conference call at 10:00 a.m. EDT

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016

BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016

- Results identify specific targets in the apoptotic pathway -

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML

BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML

Data identify a potential biomarker for future selection of BL-8040-responsive AML patients

BioLineRx To Report Annual 2015 Results On March 10, 2016

BioLineRx To Report Annual 2015 Results On March 10, 2016

Management to hold a conference call at 10:00 a.m. EST

BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment

BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment

BL-7010 receives designation as Class IIb medical device

BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer

BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer

BioLineRx management to hold conference call this morning at 10:00 am EST to further discuss this immunotherapy collaboration